论文部分内容阅读
目的探讨非小细胞肺癌(NSCLC)脑转移患者应用厄洛替尼联合全脑放射治疗的临床效果。方法选取医院接诊的非小细胞肺癌脑转移患者80例为研究对象,随机分为对照组与观察组,每组40例。对照组采用全脑放射治疗,观察组采用全脑放射治疗联合厄洛替尼治疗。观察记录2组患者的临床效果(总体缓解率)以及随访1年生存率、中位生存时间,并做对比分析。结果观察组总体缓解率为92.50%,高于对照组的75.00%,2组比较差异有统计学意义(P<0.05);观察组随访1年生存率与中位生存时间均大于对照组,2组比较差异有统计学意义(P<0.05)。结论非小细胞肺癌脑转移患者采取全脑放射治疗联合厄洛替尼治疗,不仅可以提高临床疗效,而且可以提高远期生存率,延长生存时间,值得临床推广应用。
Objective To investigate the clinical effect of erlotinib combined with whole brain radiotherapy in patients with non-small cell lung cancer (NSCLC) brain metastases. Methods Eighty patients with non-small cell lung cancer brain metastases admitted by the hospital were selected as study subjects. They were randomly divided into control group and observation group, with 40 cases in each group. The control group received whole-brain radiotherapy, and the observation group received whole-brain radiotherapy combined with erlotinib. Observe and record the clinical effect (total remission rate) of the two groups of patients, follow-up 1-year survival rate, median survival time, and do comparative analysis. Results The overall remission rate was 92.50% in the observation group, which was 75.00% higher than that in the control group. The difference between the two groups was statistically significant (P<0.05). The one-year survival rate and median survival time were significantly higher in the observation group than in the control group. 2 There was a statistically significant difference between the groups (P<0.05). CONCLUSION: Whole brain radiation combined with erlotinib treatment for brain metastases in patients with non-small cell lung cancer can not only improve the clinical efficacy, but also improve the long-term survival rate and prolong survival time. It is worthy of clinical application.